Guerbet, the specialist in contrast products for medical imaging, rose on the stock market on Friday after returning to growth in the second quarter and confirming its annual targets.

After a slight downturn in sales in the first quarter (-1.3%), the Group saw sales at constant exchange rates rise by 6.7% in the second quarter, an acceleration in line with the Group's objectives.

Over the first half as a whole, sales amounted to 378.6 million euros, up 2% on the first half of 2022. At constant
exchange rates, sales were up 2.8%.

In its press release, Guerbet stated that it was confident in its outlook for the second half of 2023, based in particular on the acceleration of price effects, with growth expected to be stronger than in the first six months of the year.

For the full year, Guerbet confirms that it is targeting sales growth in excess of 5% on a like-for-like basis and at constant exchange rates.

In terms of profitability, the Group still anticipates an adjusted Ebitda/sales margin of around 11%, with a return in 2024 of this margin to a level higher than that recorded in 2021 (14.4%).

Following this publication, Guerbet shares gained over 7% by mid-morning on the Paris Bourse, one of the strongest gains on the Paris market.

Copyright (c) 2023 CercleFinance.com. All rights reserved.